<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738595</url>
  </required_header>
  <id_info>
    <org_study_id>EVT 302/3009</org_study_id>
    <secondary_id>EUDRACT No.: 2008-002472-99</secondary_id>
    <nct_id>NCT00738595</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.</brief_title>
  <official_title>Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evotec Neurosciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinpharm International Management Holding GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Evotec Neurosciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of EVT 302, a potent and selective inhibitor of
      Monoamine Oxidase - B, in improving quit rates in chronic cigarette smokers who are motivated
      to quit smoking. EVT 302 will be compared to placebo both with and without open label
      nicotine replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The four-week continuous quit rate over the last four weeks of treatment</measure>
    <time_frame>Last 4 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>7 -week abstinence</measure>
    <time_frame>7 weeks post quit day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day point prevalence quit rate</measure>
    <time_frame>weekly for 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily cigarettes smoked</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of cigarettes smoked</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Nicotine Withdrawal Scale</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Questionnaire of Smoking Urges</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Cigarette Evaluation Questionnaire</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory investigations (Haematology &amp; biochemistry)</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 302, 5 mg once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 302 plus open label Nicotine replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus nicotine replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 302</intervention_name>
    <description>EVT 302 5 mg once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match EVT 302, 5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 302 plus open label Nicotine replacement</intervention_name>
    <description>Double-blind EVT 302 plus open label nicotine replacement</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus open label Nicotine Replacement</intervention_name>
    <description>Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoker of at least 10 cigarettes daily

          -  Motivated to quit smoking

          -  Reports at least one unsuccessful attempt to quit in the last 2 years

          -  In generally good health

          -  Provides written informed consent to participate in the sudy

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Women of child-bearing potential must agree to use acceptable contraceptive
             precautions (contraceptive pill and one barrier method)during the study and for
             2-months thereafter

          -  History of anaphylaxis

          -  History of alcohol or drug abuse

          -  History of or current significant medical or psychiatric disorder

          -  History or presence of cataract or abnormality identified by slit lamp investigation

          -  Use of other MAO inhibitors, pethidine, SSRIs, tricyclic antidepressants,nasal or oral
             decongestants or cold medicines containing ephedrine, pseudoephedrine or other
             sympathomimetics.

          -  Any medicine contraindicated for use with MAO inhibitors.

          -  Have or be a carrier of hepatitis B or c or HIV 1 or 2

          -  Use of tobacco products other than cigarettes

          -  Use of nicotine replacement therapy in the past month

          -  Received an investigational drug in the past 30 days

          -  Previous participation in a study with a MAO-B inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H D Stahl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClinPharm International, Leipzig, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evotec Study Site 2</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 3</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 8</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 4</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 5</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 7</name>
      <address>
        <city>Gorlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 1</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 6</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evotec Study Site 9</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>May 28, 2009</last_update_submitted>
  <last_update_submitted_qc>May 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr S P Jones, VP Clinical Development</name_title>
    <organization>Evotec</organization>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

